argenex (NASDAQ:ARGX) Earns “Peer Perform” Rating from Wolfe Research

argenex (NASDAQ:ARGX)‘s stock had its “peer perform” rating restated by equities research analysts at Wolfe Research in a report issued on Monday, MarketBeat reports.

A number of other research analysts have also commented on ARGX. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Evercore ISI boosted their price target on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Wedbush increased their price objective on shares of argenex from $880.00 to $1,000.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Royal Bank Of Canada raised their price objective on shares of argenex from $850.00 to $860.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Morgan Stanley lifted their target price on shares of argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a research report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus target price of $903.78.

argenex Stock Up 1.2%

ARGX stock opened at $917.93 on Monday. argenex has a twelve month low of $510.05 and a twelve month high of $934.13. The company has a market cap of $56.52 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 0.91 and a beta of 0.45. The business’s 50-day simple moving average is $821.30 and its 200 day simple moving average is $687.75.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. On average, equities research analysts anticipate that argenex will post 3.13 EPS for the current year.

Institutional Investors Weigh In On argenex

A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its holdings in argenex by 14.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after purchasing an additional 21,805 shares in the last quarter. Amundi raised its holdings in shares of argenex by 8.1% in the first quarter. Amundi now owns 6,351 shares of the company’s stock valued at $3,747,000 after buying an additional 478 shares during the last quarter. Voya Investment Management LLC lifted its position in argenex by 5.2% during the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock worth $8,822,000 after buying an additional 735 shares in the last quarter. Royal Bank of Canada grew its holdings in argenex by 0.9% during the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after acquiring an additional 353 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in argenex by 40.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,611 shares of the company’s stock worth $2,542,000 after acquiring an additional 1,328 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.